

## Amendments to the Claims

This listing of the claims will replace all prior versions, and listings, of claims in the application:

### Listing of the Claims

1. (Canceled)

2. (Currently Amended) A method of treating ~~or preventing~~ a type of cancer, comprising

administering to a subject in need of such treatment ~~or prevention~~ a composition comprising a population of complexes, said complexes comprising (a) ~~heat shock protein and/or~~ alpha-2-macroglobulin; and (b) antigenic peptides, wherein said population of complexes ~~were was~~ produced by a method comprising digesting a protein preparation comprising (i) ~~at least 50% of the different proteins present in cells of said type of cancer or~~ (ii) at least 50 different proteins present in cells of said type of cancer with one or more proteases to produce a population of antigenic peptides, and complexing the population of antigenic peptides to ~~heat shock protein or~~ alpha-2-macroglobulin in vitro; and

administering to said subject at least one treatment modality that does not comprise a heat shock protein or alpha-2-macroglobulin.

3-8. (Canceled)

9. (Currently Amended) The method of claim 2, ~~or 3~~ wherein said complexing of the population of antigenic peptides to the alpha-2-macroglobulin ~~heat shock proteins~~ is via formation of a covalent bond.

10. (Currently Amended) The method of claim 2, ~~or 3~~ wherein said complexing of the population of antigenic peptides to the alpha-2-macroglobulin ~~heat shock proteins~~ is via formation of a non-covalent bond.

11-16. (Canceled)

17. (Currently Amended) The method of claim 2, ~~or 3~~ wherein said population of

complexes is purified.

18. (Canceled)

19. (Currently Amended) The method of claim 2, 1, 2 or 3 wherein the cells of ~~same~~ said type of cancer are from a metastasis.

20. (Currently Amended) The method of claim 2, 1, 2 or 3 wherein ~~the cancer treated or prevented~~ said type of cancer is a metastasis.

21. (Canceled)

22. (Canceled)

23. (Currently Amended) The method of claim 2, 1, 2, or 3 wherein the at least one treatment modality comprises a chemotherapeutic agent, an anti-angiogenic agent, a cytokine, a biological response modifier, a hormone, an antibody, a polynucleotide, an immunostimulatory oligonucleotide, a photodynamic therapeutic agent or radiation.

24. (Canceled)

25. (Currently Amended) The method of claim 2, 1, 2, 3, 4, 5, or 6 wherein said composition is administered before, concurrently with, or after administration of the at least one treatment modality.

26. (Currently Amended) The method of claim 2, 1, 2, 3, 4, 5, or 6 wherein the subject has previously been non-responsive to treatment with said at least one treatment modality in the absence of said composition.

27. (Currently Amended) The method of claim 2, 1, 2, 3, 4, 5, or 6 wherein said administering of said composition is repeated at weekly intervals.

28. (Currently Amended) The method of claim 2, 1, 2, 3, 4, 5, or 6 wherein said administering of said composition is repeated at the same site of the subject.

29. (Currently Amended) The method of claim 2, 1, 2, 3, 4, 5, or 6 wherein said administering of said composition is intradermally or subcutaneously.

30. (Currently Amended) The method of claim 2, 1, 2, 3, 4, 5, or 6 wherein a sub-

optimal amount of said composition is administered.

31. (Currently Amended) The method of claim 2, 1, 2, 3, 4, 5, or 6 wherein a sub-optimal amount of said at least one treatment modality is administered.

32. (Currently Amended) The method of claim 2, 17, 23, 26, 30, or 31, 1, 2, 3, 4, 5, or 6 wherein the subject is human.

33. (Canceled)

34. (Canceled)

35. (Currently Amended) The method of claim 2, or 3 wherein the antigenic peptides are autologous to the subject.

36-39. (Canceled)

40. (New) The method of claim 2, 17, 23, 26, 30, or 31, wherein the composition comprises one or more adjuvants in admixture with said population of complexes.

41. (New) The method of claim 40, wherein the one or more adjuvants is selected from the group consisting of QS-21, poly[di(carboxylatophen-oxy)phosphazene, monophosphoryl lipid A, muramyl dipeptide, threonyl- muramyl dipeptide, a glucosamine disaccharide, and Leishmania elongation factor.

42. (New) The method of claim 2, wherein the composition is administered simultaneously with said at least one treatment modality which is in admixture with said population of complexes.